Aytu BioScience Inc (AYTU) - Total Assets
Based on the latest financial reports, Aytu BioScience Inc (AYTU) holds total assets worth $111.69 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Aytu BioScience Inc - Total Assets Trend (2007–2025)
This chart illustrates how Aytu BioScience Inc's total assets have evolved over time, based on quarterly financial data. Also see Aytu BioScience Inc (AYTU) total market value for the company's overall valuation and market capitalisation.
Aytu BioScience Inc - Asset Composition Analysis
Current Asset Composition (June 2025)
Aytu BioScience Inc's total assets of $111.69 Million consist of 63.8% current assets and 36.2% non-current assets. Review Aytu BioScience Inc (AYTU) financial obligations to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 24.9% |
| Accounts Receivable | $31.16 Million | 25.1% |
| Inventory | $11.43 Million | 9.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $42.20 Million | 34.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how Aytu BioScience Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AYTU stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aytu BioScience Inc's current assets represent 63.8% of total assets in 2025, an increase from 39.1% in 2007.
- Cash Position: Cash and equivalents constituted 24.9% of total assets in 2025, down from 39.1% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 33.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is intangible assets at 34.0% of total assets.
Aytu BioScience Inc Competitors by Total Assets
Key competitors of Aytu BioScience Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Aytu BioScience Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.12 | 1.03 | 0.96 |
| Quick Ratio | 1.00 | 0.87 | 0.81 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $7.35 Million | $1.81 Million | $-4.20 Million |
Aytu BioScience Inc - Advanced Valuation Insights
This section examines the relationship between Aytu BioScience Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.67 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | 4.5% |
| Total Assets | $124.18 Million |
| Market Capitalization | $21.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Aytu BioScience Inc's assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Aytu BioScience Inc's assets grew by 4.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Aytu BioScience Inc (2007–2025)
The table below shows the annual total assets of Aytu BioScience Inc from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | $124.18 Million | +4.48% |
| 2024-06-30 | $118.86 Million | -13.77% |
| 2023-06-30 | $137.84 Million | +0.16% |
| 2022-06-30 | $137.62 Million | -48.20% |
| 2021-06-30 | $265.67 Million | +73.83% |
| 2020-06-30 | $152.84 Million | +340.18% |
| 2019-06-30 | $34.72 Million | +64.87% |
| 2018-06-30 | $21.06 Million | +40.41% |
| 2017-06-30 | $15.00 Million | -38.39% |
| 2016-06-30 | $24.34 Million | +33.56% |
| 2015-06-30 | $18.23 Million | +51.69% |
| 2014-06-30 | $12.02 Million | +124174.48% |
| 2013-06-30 | $9.67K | -23.55% |
| 2012-06-30 | $12.65K | -44.62% |
| 2011-06-30 | $22.84K | -15.70% |
| 2010-06-30 | $27.09K | -35.27% |
| 2009-06-30 | $41.85K | -43.50% |
| 2008-06-30 | $74.07K | +24.13% |
| 2007-06-30 | $59.67K | -- |
About Aytu BioScience Inc
Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release o… Read more